Found 8 matching trials
GW873140 to Treat HIV-1 Infected Adults
PHASE2This study will determine which of four doses of GW873140 can safely be giv...
Location
National Institute of Allergy and Infectious Diseases (NIAID)
Observational Study of HIV-Infected Subjects With X4-Tropic or Non-Phenotypeable Virus
N/AThe purpose of this study is to measure viral tropism over time in subjects...
Location
GSK Investigational Site
Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects
PHASE3The purpose of this study is to evaluate the safety and efficacy of the CCR...
Location
GSK Investigational Site
Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Treatment-Experienced HIV-Infected Subjects
PHASE3The purpose of this study is to evaluate the safety and efficacy of the CCR...
Location
GSK Investigational Site
Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140
PHASE3The purpose of this study is to determine eligibility for one of three trea...
Location
GSK Investigational Site
GW873140 In Combination With Kaletra In HIV Infected Subjects
PHASE2This study is a 96-week study designed to evaluate the safety and efficacy ...
Location
GSK Investigational Site
GW873140 In Combination With Combivir In HIV Infected Subjects
PHASE2This study is a 96-week study designed to evaluate the safety and efficacy ...
Location
GSK Investigational Site
Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects
PHASE3The purpose of this study is to evaluate the safety and efficacy of the CCR...
Location
GSK Investigational Site